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Background: The aim of this retrospective study was to evaluate the stability of spinal metastases in gynecologic
cancer patients (pts) on the basis of a validated scoring system after radiotherapy (RT), to define prognostic factors
for stability and to calculate survival.
Methods: Fourty-four women with gynecologic malignancies and spinal bone metastases were treated at our
department between January 2000 and January 2012. Out of those 34 were assessed regarding stability using the
Taneichi score before, 3 and 6 months after RT. Additionally prognostic factors for stability, overall survival, and
bone survival (time between first day of RT of bone metastases and death from any cause) were calculated.
Results: Before RT 47% of pts were unstable and 6 months after RT 85% of pts were stable. Karnofsky performance
status (KPS) >70% (p = 0.037) and no chemotherapy (ChT) (p = 0.046) prior to RT were significantly predictive for
response. 5-year overall survival was 69% and 1-year bone survival was 73%.
Conclusions: RT is capable of improving stability of osteolytic spinal metastases from gynecologic cancer by
facilitating re-ossification in survivors. KPS may be a predictor for response. Pts who received ChT prior to RT may
require additional bone supportive treatment to overcome bone remodeling imbalance. Survival in women with
bone metastases from gynecologic cancer remains poor.
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Bone metastases are a rare occurrence in gynecologic
malignancies and in the majority of cases associated with
a poor prognosis [1-8]. Patients (pts) are usually treated
with a palliative intention to reduce pain and to preserve
functionality. Complications of spinal bone metastases
may be severe, especially metastatic spinal cord compres-
sion or pathological fractures may tremendously impair
patients’ quality of life (QoL) [9].
Treatment is usually multimodal and interdisciplinary.
One of the main therapy modalities for bone metastases
is radiotherapy (RT). Most frequently patients are treated
for pain, but existing or impending instability, neurologic* Correspondence: harald.rief@med.uni-heidelberg.de
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unless otherwise stated.symptoms due to spinal cord compression and post-
surgical RT are common indications as well [4,10]. The
stability of vertebral bodies affected by bone metastases is
an important aspect in clinical practice and for pts’ QoL.
On the one hand disability from pathologic fractures is
risked if the vertebral column is not sufficiently stabilized,
and on the other hand the usually prescribed surgical cor-
sets add a significant immobilization to the already existing
pain. However, mobilization and adequate exercises are of
high importance for this subgroup of palliative pts regard-
ing QoL [11] and reduction of the time of hospitalization.
Recently we reported on 338 pts with lung cancer in which
a significant response towards RT in terms of stability of
bone metastases was shown [12].
The purpose of this analysis was to evaluate gynecologic
cancer pts with spinal bone metastases treated at ourl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Patients’ characteristics
n %
Age (years)
















Papillary serous 2 14
Clear cell 5 36




Papillary serous 4 25
Clear cell 3 18
Leiomyosarcoma 7 44
Cervix 9 21
Squamous cell 9 100
Vulva 4 9
Squamous cell 4 100
Number of bone metastases












Abbreviation: KPS Karnofsky performance status.
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on prognostic factors for stability and on survival.
Methods
Fourty-four women with thoracic or lumbar spinal bone
metastases from gynecologic malignancies were treated
at the Department of Radiation Oncology at the University
Hospital of Heidelberg between January 2000 and January
2012. Pts’ data were collected from the Heidelberg NCT
Cancer Register. The diagnosis was based on CT, MRI or
bone scintigraphy findings. Bone metastases had to be lo-
cated in the thoracic or lumbar spine. After 6 months 34
pts were alive and were, therefore, included in the statistical
stability analysis; all 44 pts were included in the statistical
survival analysis. Preexisting CT scans were reviewed re-
garding stability of the osteolytic lesions using the Taneichi
score [13]. In pts with more than one metastasis per verte-
bral body, the one with the worst Taneichi score was
assessed. Accordingly, osteolytic metastases with subtypes
A to C were classified as stable, and subtypes D to F were
classified as unstable. Response was defined as a change
from unstable to stable after RT at 3 or 6 months. Pts’
performance status was evaluated with the Karnofsky
performance status (KPS) [14]. The characteristics of all
pts included in this study are summarized in Table 1.
Median follow-up was 6.5 years.
RT was planned as virtual simulation and performed
over a dorsal photon field with the energy 6 MV. PTV
covered the vertebral body as well as the vertebral body
immediately above and below. Median delivered dose
was 30 Gy (range 20–40 Gy) in single fractions of 3 Gy
(2–4 Gy) (Table 2).Table 2 Treatment
Characteristics n %
Radiotherapy dose completed (Gy)
Single dose (median, range) 3 (2–4)






Treatment for primary site
Chemotherapy yes 17 39
no 27 61
Other treatment for bone metastases
Surgical corset yes 8 18
no 36 82
Bisphosphonates yes 19 43
no 25 57
Figure 1 Taneichi Score: (a) Taneichi Score of the thoracic spine, (b) Taneichi score of the lumbar spine.
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Table 4 Test of symmetry for Taneichi-Score
Subtypes 6 months after radiotherapy
A B C D E F Total
Subtypes before
radiotherapy
A 8 0 0 0 0 0 8
B 0 2 0 0 0 0 2
C 1 2 5 0 0 0 8
D 0 2 6 1 0 0 9
E 0 0 1 1 1 0 3
F 0 0 2 0 0 2 4
Total 9 6 14 2 1 2 34
This Bowker Test showed the distribution of subtypes of Taneichi-Score before
and 6 month after radiation therapy. Asymmetry was apparent (p < 0.001) and
the correlation (kappa = 0.614) was good. The evaluation of the distribution of
subtypes A to F showed a major change in the direction of improvement over
the course of time. Deterioration occurred in no cases, improvement in 44%
(n = 15). No change was seen in 56% (n = 19) of the cases.
Table 5 Response to radiotherapy after 6 months
Non response Response
p-value
n % n %
Primary malignancy 0.794
Uterus 9 75 3 25
Ovary 6 55 5 45
Cervix 5 71 2 29
Vulva 2 67 1 33
Fallopian tube 1 100 0 0
KPS 0.037
≤70% 10 71 4 29
> 70% 7 40 13 60
Chemotherapy prior to RT 0.046
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version 9.3 (SAS Institute, Cary, NC, USA). A p-value of
p < .05 was considered statistically significant (Chi square
and Log-rank test). Overall survival was defined as the time
between first diagnosis of malignancy until death from any
cause, whereas bone survival was considered to be the time
between first day of RT of bone metastases until death from
any cause. Survival was plotted according to Kaplan and
Meier. Bowker’s test and kappa statistics were calculated
to evaluate distribution of the Taneichi score over time.
Univariate logistic regression analysis was performed to
evaluate possible predictors for stability after 6 months.
Results
After 6 months 34 pts were alive and were assessed ac-
cording to the Taneichi score prior to RT, 3 months and
6 months after RT based on CT imaging.
Bone metastases were located in the thoracic spine in
34% (n = 15), in the thoracic and lumbar spine in 11%
(n = 5) and in the lumbar spine in 55% (n = 24) of the
pts. Most frequent subtype according to Taneichi was
D (27%; n = 9) (Figure 1). Mean number of spinal me-
tastases per patient was 2 (range 1–7). No pathological
fractures occurred.
Sixteen (47%) women had unstable and 18 (53%) pts
had stable bone metastases before RT. After 3 months,
62% (n = 21) of metastases were classified as stable and
85% (n = 29) after 6 months (Table 3). No change from
stable to unstable was observed. Taneichi subtypes im-
proved in 44% (n = 15) and showed no change in 56%
(n = 19) after 6 months. Asymmetry was apparent and
correlation was good (p < .001; kappa = .614) (Table 4).
KPS >70% prior to RT was significantly correlated with
response (p = .037). Additionally pts who did not receive
chemotherapy (ChT) prior to RT were significantly more
likely to respond (p = .046). Age, prescribed dose, entity
of malignancy, location of spinal metastases, number
of spinal metastases, bisphosphonate therapy, and use
of stabilizing surgical corset were not predictive for re-





Stability after 3 months
Unstable 13 38
Stable 21 62
Stability after 6 months
Unstable 5 15
Stable 29 85Fourteen pts (32%) died during follow-up, resulting in
an overall survival of 69% after 5 years and a bone survival
of 73% after 1 year (Figures 2 and 3).
Discussion
Bone metastases are comparatively rare in gynecologic
malignancies [1-5]. Pts are limited in their quality of lifeYes 12 86 2 14
No 11 55 9 45
Location of spinal metastases 0.279
Thoracic 9 75 3 25
Thoracic and lumbar 3 100 0 0
Lumbar 11 58 8 42
Bisphosphonates during RT 0.914
Yes 10 67 5 33
No 13 68 6 32
Surgical corset 0.523
Yes 4 80 1 20
No 19 65 10 35
Figure 2 Overall survival. Kaplan-Meier curve of overall survival of patients with stable and unstable bone metastases.
Figure 3 Bone survival. Kaplan-Meier curve of bone survival of patients with stable and unstable bone metastases.
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fractures and neurologic consequences such as paraplegia.
Stability of spinal metastases is a frequently raised clinical
concern in this context and the Taneichi score is an estab-
lished tool for classification of spinal metastases regarding
risk of pathologic fracture or bone instability [13]. In the
thoracic spine risk factors are tumor size, and degree of
costovertebral joint destruction [15]. In the lumbar part of
the spine tumor size and degree of pedicle destruction are
the main concern [13]. In our cohort almost half of the
patients had unstable metastases at diagnosis. Palliative RT
constitutes a potent therapeutic modality for treatment of
pain and providing re-ossification [12].
Stability outcome of RT in spinal metastases from
gynecologic cancer is still unknown and in previous
studies on spinal metastases therapeutic response was
only measured in terms of pain control. We were able
to demonstrate that RT is capable of improving stabil-
ity due to re-ossification of osteolytic lesions; only 15%
of spinal bone metastases in our cohort of women with
gynecologic malignancies remained unstable 6 months
after application of RT. The stability before RT was
only 53%; whereas 85% were stable after RT.
ChT prior to RT was significantly associated with non-
response in our analysis (p = .046). Chemotherapeutics
may lead to imbalanced bone remodeling and can cause
osteoporosis which in term may prevent response after
RT [16]. However, we cannot rule out coincidence because
of the small number of pts in our analysis; especially since
this is contradictive to the findings of our recent larger ana-
lysis of pts with lung cancer [12]. KPS >70% was signifi-
cantly associated with response to RT (p = .037) which may
be explained by continued physical strain to the bones in
mobile pts [17,18].
Overall survival and bone survival were poor and coin-
cide with results from the literature. The longest reported
overall survival and bone survival in the literature were
46 months and 25 months respectively [1-8].
Conclusion
RT is an effective palliative treatment of spinal bone me-
tastases and is capable of improving stability in pts with
gynecologic malignancies. KPS may be a predictor for
positive response to RT. Pts who underwent ChT prior
to RT may require additional bone supportive treatment
(bisphosphonates, denosumab, calcium and vitamin D)
to overcome bone remodeling imbalance. Survival in pts
with bone metastases remains low.
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